Albert W. Gianchetti
Vorstandsvorsitzender bei Xylocor Therapeutics, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Ronald Crystal | M | - |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | 11 Jahre |
Todd K. Rosengart | M | - |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | 11 Jahre |
Jennifer Augusti | F | - |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
A. Davis | M | 57 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Alan Colowick | M | 61 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | 6 Jahre |
Fouad Azzam | M | 57 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Glenn Batchelder | M | 63 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Daniel Hetu | M | - |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
John Paul de Koning | M | 55 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Aidan King | M | 53 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | 3 Jahre |
Nikhil Thatte | M | - |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Lizzie Ngo | M | - |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jan Smilek | M | 57 | 2 Jahre | |
Frederick H. Graff | M | - | 2 Jahre | |
John Joseph Feeney | M | 68 | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 15 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Albert W. Gianchetti
- Persönliches Netzwerk